CYP1A2 and tobacco interaction : a major pharmacokinetic challenge during smoking cessation
Smoking cessation is underestimated in terms of drug interactions. Abrupt smoking cessation is common in cases of emergency hospitalization and restrictions of movement. Tobacco is a known cytochrome P450 1A2 (CYP1A2) inducer, its consumption and withdrawal can lead to major pharmacokinetic drug interactions. Nevertheless, references do exist, but may have different results between them. The objective of our work was to establish the broadest and most consensual list as possible of CYP1A2 substrates treatments and propose a pharmacological approach. We searched the widest possible list of CYP1A2 substrates based on various international references. We compared the references and defined probability and reliability scores of our results to sort the substances based on the scores. For the 245 substances identified as CYP1A2 substrates, we focused on the 63 CYP1A2 substrates with both probability and reliability scores >50%. Our work establishes adaptive pharmacological approaches for the management of patients initiating smoking cessation which must be integrated into the management of smoking cessation. Pharmacologists can now adopt adaptive pharmacological approaches to complement patient-specific clinical information about smoking cessation by considering pharmacokinetic risk. This work establishes an unprecedented list. It should guide in the care of patients initiating smoking cessation to prevent pharmacokinetic drug interactions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Drug metabolism reviews - 53(2021), 1 vom: 15. Feb., Seite 30-44 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barrangou-Poueys-Darlas, Malcolm [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Addiction medicine |
|---|
| Anmerkungen: |
Date Completed 04.04.2022 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/03602532.2020.1859528 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318903709 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318903709 | ||
| 003 | DE-627 | ||
| 005 | 20231227130413.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03602532.2020.1859528 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1224.xml |
| 035 | |a (DE-627)NLM318903709 | ||
| 035 | |a (NLM)33325257 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barrangou-Poueys-Darlas, Malcolm |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CYP1A2 and tobacco interaction |b a major pharmacokinetic challenge during smoking cessation |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2022 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Smoking cessation is underestimated in terms of drug interactions. Abrupt smoking cessation is common in cases of emergency hospitalization and restrictions of movement. Tobacco is a known cytochrome P450 1A2 (CYP1A2) inducer, its consumption and withdrawal can lead to major pharmacokinetic drug interactions. Nevertheless, references do exist, but may have different results between them. The objective of our work was to establish the broadest and most consensual list as possible of CYP1A2 substrates treatments and propose a pharmacological approach. We searched the widest possible list of CYP1A2 substrates based on various international references. We compared the references and defined probability and reliability scores of our results to sort the substances based on the scores. For the 245 substances identified as CYP1A2 substrates, we focused on the 63 CYP1A2 substrates with both probability and reliability scores >50%. Our work establishes adaptive pharmacological approaches for the management of patients initiating smoking cessation which must be integrated into the management of smoking cessation. Pharmacologists can now adopt adaptive pharmacological approaches to complement patient-specific clinical information about smoking cessation by considering pharmacokinetic risk. This work establishes an unprecedented list. It should guide in the care of patients initiating smoking cessation to prevent pharmacokinetic drug interactions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cytochrome P450 | |
| 650 | 4 | |a addiction medicine | |
| 650 | 4 | |a drug interactions | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a smoking cessation | |
| 650 | 4 | |a tobacco | |
| 650 | 7 | |a CYP1A2 protein, human |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 CYP1A2 |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 700 | 1 | |a Guerlais, Marylène |e verfasserin |4 aut | |
| 700 | 1 | |a Laforgue, Edouard-Jules |e verfasserin |4 aut | |
| 700 | 1 | |a Bellouard, Ronan |e verfasserin |4 aut | |
| 700 | 1 | |a Istvan, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Chauvin, Pascale |e verfasserin |4 aut | |
| 700 | 1 | |a Guillet, Jean-Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Jolliet, Pascale |e verfasserin |4 aut | |
| 700 | 1 | |a Gregoire, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Victorri-Vigneau, Caroline |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug metabolism reviews |d 1973 |g 53(2021), 1 vom: 15. Feb., Seite 30-44 |w (DE-627)NLM000049530 |x 1097-9883 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2021 |g number:1 |g day:15 |g month:02 |g pages:30-44 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/03602532.2020.1859528 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2021 |e 1 |b 15 |c 02 |h 30-44 | ||